Thursday, April 11, 2019, Anaheim, California, 6:00 PM – 8:00 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A 6-Part CNE Symposia Series Held During the ONS 44th Annual Congress

PART 5 — Breast Cancer

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room:
Grand Ballroom E-K (Lobby Level)
5:30 PM – 6:00 PM
Registration and Dinner Buffet

6:00 PM – 8:00 PM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Jamie Carroll, APRN, MSN, CNP
Mayo Clinic
Rochester, Minnesota

Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Elizabeth O’Reilly, RN, NP, MSN, MPH
Nurse Practitioner, Breast Oncology
Susan F Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Boston, Massachusetts

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical
Trials Education
University of California, San Francisco
Medical Center
UCSF Helen Diller Family Comprehensive
Cancer Center
San Francisco, California

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a symposium supported by Genentech, Lilly, Merck, Novartis and Puma Biotechnology Inc during the Oncology Nursing Society’s (ONS) 44th Annual Congress, April 11-14, 2019 in Anaheim, California. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
5:30 PM – 6:00 PM — Registration and Dinner Buffet
6:00 PM – 8:00 PM — Educational Program

Cases Presented Will Include Discussion of the Following Topics:

  • Clinical and biologic factors affecting the use of pertuzumab, T-DM1 and neratinib for patients with early HER2-positive breast cancer (BC)
  • Approved and investigational approaches for HER2-positive metastatic BC (mBC)
  • Current role of immune checkpoint inhibition in the treatment of mBC
  • Evolving treatment paradigms for patients with advanced ER-positive, HER2-negative BC: Current clinical role of CDK4/6 inhibitors and ongoing evaluation of PI3 kinase inhibition
A detailed agenda will be available in the coming weeks

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer (BC).

Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:

  • Apply existing and emerging research data to the diagnostic, therapeutic and supportive care of patients with early and advanced BC.
  • Implement a long-term clinical plan for the management of early and advanced HER2-positive BC, incorporating existing, recently approved and investigational targeted treatments.
  • Recognize the FDA-endorsed indications for the commercially available CDK4/6 inhibitors, and discern how these agents can be optimally employed in the nonresearch care of patients with ER-positive metastatic BC (mBC).
  • Develop an understanding of the frequency and potential biologic implications of PIK3CA mutations in patients with ER-positive mBC previously treated with endocrine therapy, and appreciate published research data documenting the efficacy and safety of novel agents targeting this abnormality.
  • Develop a plan to manage the side effects associated with available and recently approved systemic therapies to support quality of life and continuation of treatment.
  • Appreciate the biologic rationale for and available data with novel immunotherapeutic approaches to facilitate their introduction into clinical practice for appropriate patients with mBC.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 2 contact hours is provided by RTP.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CME/CNE planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Genentech, Lilly, Merck, Novartis and Puma Biotechnology Inc.

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room: 
Grand Ballroom E-K (Lobby Level)

The Anaheim Marriott is the headquarters hotel for the 2019 ONS Congress and is conveniently located near the Anaheim Convention Center (0.2 miles).


This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

There is no registration fee for this event. However, preregistration is highly recommended as seating is limited.

Registration for clinicians in practice

• I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Standby registration for nonclinicians/industry professionals*

For all other professionals, we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information. Should seats become available for the program, we will notify you.

Standby registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CNE programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.